News
GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...
GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...
21h
Pharmaceutical Technology on MSNNICE approves GSK’s belantamab mafodotin for blood cancerNHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.
This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but this could mean ...
Twin pipelines will carry liquefied petroleum gas from the country's largest oilfield for conversion into polymers ...
An asthma drug biotech that was acquired in a deal with GSK plc worth up to $1.4 billion is now at the center of a lawsuit, ...
Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...
Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...
The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep ...
China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results